|
[1] XU L,ZHENG YQ,SHI Z,et al. Influencing factors for the prognosis of primary biliary cholangitis[J]. J Clin Hepatol,2019,35(8):1870-1873.(in Chinese)徐黎，郑玥琪，时桢，等．原发性胆汁性胆管炎预后的影响因素[J]．临床肝胆病杂志，2019,35(8):1870-1873.
|
|
[2] HIRSCHFIELD GM,DYSON JK,ALEXANDER G,et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut,2018,67(9):1568-1594.
|
|
[3] KARIMI M,BRAZIER J. Health,Health-Related Quality of Life,and Quality of Life:What is the difference?[J]. Pharmacoeconomics,2016,34(7):645-649.
|
|
[4] WARE JE Jr,GANDEK B. Overview of the SF-36 health survey and the International Quality of Life Assessment(IQOLA)project[J]. J Clin Epidemiol,1998,51(11):903-912.
|
|
[5] ZHENG YB. Influencing factors of quality of life in hospitalized patients with chronic liver disease[J]. Guangxi Med J,2018,40(7):788-791.(in Chinese)郑亚彬．慢性肝病住院患者生存质量的影响因素研究[J]．广西医学，2018,40(7):788-791.
|
|
[6] GOLOVNOVA EV,LIU I,TSAREGORODTSEVA TM,et al. Primary biliary cirrhosis:12-year experience in observation[J].Ter Arkh,2003,75(2):26-30.
|
|
[7] RANNARD A,BUCK D,JONES DE,et al. Assessing quality of life in primary biliary cirrhosis[J]. Clin Gastroenterol Hepatol,2004,2(2):164-174.
|
|
[8] WONG GL,LAW FM,WONG VW,et al. Health-related quality of life in Chinese patients with primary biliary cirrhosis[J]. J Gastroenterol Hepatol,2008,23(4):592-598.
|
|
[9] JACOBY A,RANNARD A,BUCK D,et al. Development,validation,and evaluation of the PBC-40,a disease specific health related quality of life measure for primary biliary cirrhosis[J]. Gut,2005,54(11):1622-1629.
|
|
[10] WANG HT,REN LM,LIU Y,et al. Evaluation of SF-12 health survey scale[J]. Chin J Gen Pract,2015,14(7):574-576.(in Chinese)王海棠，任利民，刘瑶，等．SF-12健康调查量表的评价研究现状[J]．中华全科医师杂志，2015,14(7):574-576.
|
|
[11] WONG LL,FISHER HF,STOCKEN DD,et al. The impact of autoimmune hepatitis and its treatment on health utility[J].Hepatology,2018,68(4):1487-1497.
|
|
[12] WANG Z,LIU ZW,ZENG XY,et al. Health-related quality of life in patients with colorectal cancer precancerous lesions on EQ-5D-5L[J]. Pract Oncol J,2018,32(4):320-326.(in Chinese)王志，刘忠卫，曾雪芸，等．基于EQ-5D-5 L的结直肠癌癌前病变患者健康相关生命质量研究[J]．实用肿瘤学杂志，2018,32(4):320-326.
|
|
[13] LYU ZW,WANG QX,MA X. Assessment of the quality of life associated with autoimmune liver disease[J]. Int J Dig Dis,2019,39(2):73-76.(in Chinese)吕珠婉，王绮夏，马雄．自身免疫性肝病的健康相关生活质量评估[J]．国际消化病杂志，2019,39(2):73-76.
|
|
[14] YOUNOSSI ZM,KIWI ML,BOPARAI N,et al. Cholestatic liver diseases and health-related quality of life[J]. Am J Gastroenterol,2000,95(2):497-502.
|
|
[15] CHARATCHAROENWITTHAYA P,TALWALKAR JA,ANGULO P,et al. Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid[J]. Dig Dis Sci,2010,55(2):476-483.
|
|
[16] ZEC S,POPOVIC D,MATOVIC V,et al. Translation and validation of the Serbian primary biliary cholangitis-40 questionnaire[J]. PLo S One,2017,12(4):e0175697.
|
|
[17] RASZEJA-WYSZOMIRSKA J,WUNSCH E,KRAWCZYK M,et al. Assessment of health related quality of life in polish patients with primary biliary cirrhosis[J]. Clin Res Hepatol Gastroenterol,2016,40(4):471-479.
|
|
[18] MILOVANOVIC T,POPOVIC D,STOJKOVIC LALOSEVIC M,et al. Quality of life in patients with primary biliary cholangitis:A single center experience in Serbia[J]. Dig Dis,2020.[Online ahead of print]
|
|
[19] KAPS L,GRAMBIHLER A,YEMANE B,et al. Symptom burden and treatment response in patients with primary biliary cholangitis(PBC)[J]. Dig Dis Sci,2019.[Online ahead of print]
|
|
[20] YAGI M,TANAKA A,ABE M,et al. Symptoms and healthrelated quality of life in Japanese patients with primary biliary cholangitis[J]. Sci Rep,2018,8(1):12542.
|
|
[21] ZHANG S,WANG L,ZHANG LL,et al. Analysis of the relationship between health-related quality of life(primary biliary cholangitis-40)and clinical presentations of patients with primary biliary cholangitis[J]. Chin J Rheumatol,2018,22(12):798-801.(in Chinese)张硕，王立，赵丽伶，等．原发性胆汁性胆管炎生活质量指标PBC-40与临床指标相关性分析[J]．中华风湿病学杂志，2018,22(12):798-801.
|
|
[22] KRAWCZYK M,KOZ'MA M,SZYMAN'SKA A,et al. Effects of liver transplantation on health-related quality of life in patients with primary biliary cholangitis[J]. Clin Transplant,2018,32(12):e13434.
|
|
[23] CARBONE M,MELLS GF,PELLS G,et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J]. Gastroenterology,2013,144(3):560-569. e7; quiz e13-e14.
|
|
[24] KHANNA A,JOPSON L,HOWEL D,et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis:A phase 2 randomized controlled trial[J]. Hepatology,2019,70(5):1646-1657.
|
|
[25] MONTALI L,TANAKA A,RIVA P,et al. A short version of a HRQo L questionnaire for Italian and Japanese patients with primary biliary cirrhosis[J]. Dig Liver Dis,2010,42(10):718-723.
|
|
[26] JONES D,PATANWALA I,NEWTON JL,et al. Comparison of the PBC-40 and PBC-27 tools for quality of life assessment in english speaking primary biliary cirrhosis patients[J]. Gut,2011:60(Suppl 1):a243.
|
|
[27] ALRUBAIY L,MELLS G,FLACK S,et al. PBC-10:A short quality of life measure for clinical screening in primary biliary cholangitis[J]. Aliment Pharmacol Ther,2019,50(11-12):1223-1231.
|
|
[28] ZAKHARIA K,TABIBIAN A,LINDOR KD,et al. Complications,symptoms,quality of life and pregnancy in cholestatic liver disease[J]. Liver Int,2018,38(3):399-411.
|
|
[29] KHANNA A,LEIGHTON J,LEE WONG L,et al. Symptoms of PBC-pathophysiology and management[J]. Best Pract Res Clin Gastroenterol,2018,34-35:41-47.
|
|
[30] JIN XY,KHAN TM. Quality of life among patients suffering from cholestatic liver disease-induced pruritus:A systematic review[J]. J Formos Med Assoc,2016,115(9):689-702.
|
|
[31] GOSSARD AA,LINDOR KD. Current and promising therapy for primary biliary cholangitis[J]. Expert Opin Pharmacother,2019,20(9):1161-1167.
|
|
[32] JOPSON L,JONES DE. Fatigue in primary biliary cirrhosis:Prevalence,pathogenesis and management[J]. Dig Dis,2015,33(Suppl 2):109-114.
|
|
[33] LEE JY,DANFORD CJ,TRIVEDI HD,et al. Treatment of fatigue in primary biliary cholangitis:A systematic review and meta-analysis[J]. Dig Dis Sci,2019,64(8):2338-2350.
|
|
[34] DE VLOO C,NEVENS F. Cholestatic pruritus:An update[J].Acta Gastroenterol Belg,2019,82(1):75-82.
|
|
[35] HEGADE VS,MELLS GF,FISHER H,et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom[J]. Clin Gastroenterol Hepatol,2019,17(7):1379-1387. e3.
|
|
[36] TRIVEDI HD,DANFORD CJ,GOYES D,et al. Osteoporosis in primary biliary cholangitis:Prevalence,impact and management challenges[J]. Clin Exp Gastroenterol,2020,13:17-24.
|
|
[37] DYSON JK,WILKINSON N,JOPSON L,et al. The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis[J]. Aliment Pharmacol Ther,2016,44(10):1039-1050.
|
DownLoad: